Eidos Therapeutics, which is developing a novel oral therapy for rare neurodegenerative diseases, raised $106 million by offering 6.25 million shares at $17, the high end of the range of $15 to $17. Eidos Therapeutics plans to list on the Nasdaq under the symbol EIDX. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.
